Intensity Therapeutics, Inc.
Late-stage clinical biotechnology company developing INT230-6, an engineered cytotoxic formulation administered by intratumoral injection for solid tumors including sarcomas and breast cancer.
8-KNov 5Latest SEC filing
Nov 3Latest story
November 2026
August 2026